News Releases
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
06 27 2024 Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report. This year's report provides information on the company's...
-
06 26 2024 Transaction to broaden access to Quest's innovative and cost-effective services for providers and patients in Minnesota and western Wisconsin SECAUCUS, N.J. and MINNEAPOLIS, June 26, 2024...
-
06 19 2024 Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2024 financial results on Tuesday, July 23, 2024, before the...
-
06 11 2024 PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a...
-
05 31 2024 Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer...